ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 859

Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis

Sophia Lionaki1, Clio Mavragani2, George Liapis3, George Somarakis4, John Boletis1, Alexandros A. Drosos5, Athanasios G. Tzioufas6 and Haralampos M. Moutsopoulos6, 1Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, 2Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, 3Pathology, Laiko Hospital, Department of Pathology, Athens, Greece, 4Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, 5Dept of Internal Medicine, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, 6Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA, glomerulonephritis and histopathologic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Prompt, aggressive therapy is vital for anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In this regard, we aimed to identify predictors of distinct renal histopathological classes at the time of clinical diagnosis.

Methods: An inception cohort of patients with biopsy proven ANCA-associated GN was studied retrospectively. Demographics, clinical, laboratory, serological and radiological parameters were analyzed. Patients were classified on the basis of renal histopathology, according to the report by Berden (1) et al into: focal class (≥50% normal glomeruli that were not affected by the disease process), crescentic class (≥50% of glomeruli with cellular crescents), sclerotic class (≥50% of glomeruli with global sclerosis), while all remaining biopsies were by definition not characterized by any of the predominant glomerular phenotypes and were classified as mixed class. Clinical phenotypes were assigned according to the second Chapel Hill vasculitides nomenclature Consensus Conference (2). A risk score was developed for each histopathological class using univariate and logistic regression analyses.

Results:

Of 147 eligible patients (136 from the University of Athens and 11 from the University of Ioannina), 105 had biopsy proven renal involvement. None of these patients had received any kind of immunosuppressive treatment at the time of kidney biopsy. Twenty out of the 105 pateints with renal involvement were excluded as they were younger than 16 years and had inadequate biopsy specimens (<10 glomeruli). Thus, the final study population consisted of 85 ANCA positive patients with biopsy proven GN.

Variables independently associated with focal class included disease duration up to diagnosis < 8 weeks, absence of red blood cell (RBC) casts by urine microscopy and eGFR > 49ml/min/1.73m2; with crescentic class > 40 erythrocytes/hpf, identification of RBC casts in urine, ear nose and throat (ENT) involvement and eGFR < 49ml/min/1.73m2; with mixed class age > 54 years, male gender, and absence of ENT involvement. In the presence of 2 or 3 risk factors a predictive risk score of each histopathological class was calculated: odds ratio (OR), 95% confidence intervals (CI), for focal class (≥2 risk factors) 17.5 (95% CI) [4.9-62.9], 38.0 [6.8-213.7] for crescentic class (≥3 risk factors), and 8.3 [1.0-67.5] (≥2 risk factors) for mixed class.

Conclusion: We propose a predictive algorithm of specific histolopathological classes of ANCA-associated GN, which might provide a crude estimation of the disease activity in the glomeruli at presentation. This tool might assist the clinician in making decisions regarding the level of intensity of inductive immunosuppressive therapy at clinical diagnosis.

References:

1.Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. Journal of the American Society of Nephrology : 2010;21(10):1628-36.


Disclosure: S. Lionaki, None; C. Mavragani, None; G. Liapis, None; G. Somarakis, None; J. Boletis, None; A. A. Drosos, None; A. G. Tzioufas, None; H. M. Moutsopoulos, None.

To cite this abstract in AMA style:

Lionaki S, Mavragani C, Liapis G, Somarakis G, Boletis J, Drosos AA, Tzioufas AG, Moutsopoulos HM. Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/predictors-of-renal-histopathology-in-antineutrophil-cytoplasmic-antibody-associated-glomerulonephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-renal-histopathology-in-antineutrophil-cytoplasmic-antibody-associated-glomerulonephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology